Your AI-Trained Oncology Knowledge Connection!

Frontline Treatment of Acute Myeloid Leukemia : Episode 10

Management of Cytopenia in Patients on Venetoclax + Azacitidine Therapy

August 18, 2022

By Hetty E. Carraway, MD
Eytan Stein, MD

Video

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

EP: 1.Overview of Acute Myeloid Leukemia (AML)

EP: 2.Diagnosis and Cytogenetic Testing in AML

EP: 3.The Goals of Treatment in AML

EP: 4.Frontline Treatment Options for Patients with AML

EP: 5.Intensive Induction Therapy In AML

EP: 6.Treatment Options for Secondary AML

EP: 7.Treatment Options for AML Patients with IDH2, RUNX1, or DNMT3A Mutations

EP: 8.Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine

EP: 9.Case Presentation: An 81-Year-Old Male with AML

EP: 10.Management of Cytopenia in Patients on Venetoclax + Azacitidine Therapy

EP: 11.The Importance of Bone Marrow Biopsies in AML Patients on Venetoclax Treatment

EP: 12.Unmet Needs and the Future of AML Treatment

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos

2 experts in this video

2 experts in this video

2 experts in this video

2 experts in this video

2 experts in this video

2 experts in this video

Related Content

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

Read More

$Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML$

Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

Read More

$FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML$

FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

Read More

$NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis$

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

Caroline Seymour

Read More

$Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML$

Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML

Read More

FDA Receives New Drug Application for Ziftomenib in NPM1-Mutant R/R AML

FDA Receives New Drug Application for Ziftomenib in NPM1-Mutant R/R AML

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the KOMET-001 trial.

Read More

Related Content

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

Read More

$Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML$

Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

Read More

$FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML$

FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

Read More

$NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis$

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

Caroline Seymour

Read More

$Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML$

Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML

Read More

FDA Receives New Drug Application for Ziftomenib in NPM1-Mutant R/R AML

FDA Receives New Drug Application for Ziftomenib in NPM1-Mutant R/R AML

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the KOMET-001 trial.

Read More

CancerNetwork.com

OncNursingNews.com

Do Not Sell My Information

Terms & Conditions

Editorial Board

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.